Direct oral anticoagulants
New anticoagulant agents, called “direct oral anticoagulants”, arrive on the market. These drugs (dabigatran, rivaroxaban, apixaban, edoxaban) offer an alternative to VKAs and heparins. Their main advantage lies in the fact that fixed doses can be given, without regular laboratory monitoring (except in special cases).